Treatment of Locally Advanced and Metastatic Salivary Gland Cancer: A 10-year Experience of an Oncology Center in Portugal
DOI:
https://doi.org/10.20344/amp.22800Keywords:
Molecular Targeted Therapy, Salivary Gland Neoplasms/drug therapyAbstract
Introduction: Scientific evidence regarding salivary gland cancer systemic treatment is limited and the therapeutic approach to locally advanced or metastatic disease is mainly based on consensus. This study aimed to evaluate treatment patterns and outcomes in patients with advanced salivary gland cancer.
Methods: We conducted a retrospective cohort study in a comprehensive cancer center in Portugal, including adult patients diagnosed with primary malignant salivary gland tumors between 2012 and 2021. Data on demographics, tumor characteristics, treatments, and outcomes were collected from institutional cancer registries and electronic medical records. The study was approved by the institutional Ethics Committee.
Results: A total of 116 patients with salivary gland cancer were identified and, of these, 45 had locally advanced or metastatic disease: 24 received systemic anti-neoplastic treatment and 21 received best supportive care. One-year overall survival in systemic anti-neoplastic treatment group was 70% (versus 14% in best supportive care group, p < 0.001) and progression-free survival was 37%. The most commonly used systemic treatment was chemotherapy (n = 29, 59%). Seven patients (14%) received androgen deprivation therapy, and two patients (4%) received other targeted therapy (olaparib and erdafitinib).
Conclusion: Systemic treatment was associated with significantly improved survival in patients with advanced salivary gland cancer. Despite the heterogeneity of therapeutic approaches, including emerging biomarker-driven therapies, clinical decision-making remains largely consensus-based. These findings underscore the need for further research to support personalized treatment strategies and guide evidence-based care.
Downloads
References
Speight PM, Barrett AW. Salivary gland tumours: diagnostic challenges and an update on the latest WHO classification. Diagn Histopathol. 2020;26:147-58. DOI: https://doi.org/10.1016/j.mpdhp.2020.01.001
Zurek M, Fus L, Niemczyk K, Rzepakowska A. Salivary gland pathologies: evolution in classification and association with unique genetic alterations. Eur Arch Otorhinolaryngol. 2023;280:4739-50. DOI: https://doi.org/10.1007/s00405-023-08110-w
International Agency for Research on Cancer. Head and neck tumours, vol. 9. 5th ed. WHO Classification of Tumours. Geneva: World Health Organization; 2022.
Son E, Panwar A, Mosher CH, Lydiatt D. Cancers of the major salivary gland. J Oncol Pract. 2018;14:99-108. DOI: https://doi.org/10.1200/JOP.2017.026856
van Herpen C, Vander Poorten V, Skalova A, Terhaard C, Maroldi R, van Engen A, et al. Salivary gland cancer: ESMO-European Reference Network on Rare Adult Solid Cancers (EURACAN) clinical practice guideline for diagnosis, treatment and follow-up. ESMO Open. 2022;7:100602. DOI: https://doi.org/10.1016/j.esmoop.2022.100602
International Agency for Research on Cancer. Global Cancer Observatory: Cancer Today. [cited 2024 Nov 08]. Available from: https://gco.iarc.fr/en.
Geiger JL, Ismaila N, Beadle B, Caudell JJ, Chau N, Deschler D, et al. Management of salivary gland malignancy: ASCO Guideline. J Clin Oncol. 2021;39:1909-41. DOI: https://doi.org/10.1200/JCO.21.00449
Locati LD, Ferrarotto R, Licitra L, Benazzo M, Preda L, Farina D, et al. Current management and future challenges in salivary glands cancer. Front Oncol. 2023;13:1264287. DOI: https://doi.org/10.3389/fonc.2023.1264287
Sarradin V, Digue L, Vergez S, Thariat J, Fakhry N, Chabrillac E, et al. Systemic therapies for salivary gland carcinoma (excluding adenoid cystic carcinoma): REFCOR recommendations by the formal consensus method. Eur Ann Otorhinolaryngol Head Neck Dis. 2024;141:280-5. DOI: https://doi.org/10.1016/j.anorl.2023.11.004
Todorovic E, Dickson BC, Weinreb I. Salivary gland cancer in the era of routine next-generation sequencing. Head Neck Pathol. 2020;14:311-20. DOI: https://doi.org/10.1007/s12105-020-01140-4
IPO-Porto. Relatório e Contas 2022. [cited 2024 Dec 31]. Available from: https://ipoporto.pt/wpsite_2020/wp-content/uploads/2024/03/RC_2022.pdf.
World Health Organization. International statistical classification of diseases and related health problems 10th revision. [cited 2024 Dec 31]. Available from: https://iris.who.int/handle/10665/42980.
World Health Organization. International Classification of Diseases for Oncology, 3rd ed. Geneva: WHO; 2013.
Gebhardt BJ, Ohr JP, Ferris RL, Duvvuri U, Kim S, Johnson JT, et al. Concurrent chemoradiotherapy in the adjuvant treatment of high-risk primary salivary gland malignancies. Am J Clin Oncol. 2018;41:888-93. DOI: https://doi.org/10.1097/COC.0000000000000386
Kang NW, Kuo YH, Wu HC, Ho CH, Chen YC, Yang CC. No survival benefit from adding chemotherapy to adjuvant radiation in advanced major salivary gland cancer. Sci Rep. 2022;12:20862. DOI: https://doi.org/10.1038/s41598-022-25468-9
Hsieh RC, Chou YC, Hung CY, Lee LY, Venkatesulu BP, Huang SF, et al. A multicenter retrospective analysis of patients with salivary gland carcinoma treated with postoperative radiotherapy alone or chemoradiotherapy. Radiother Oncol. 2023;188:109891. DOI: https://doi.org/10.1016/j.radonc.2023.109891
Hsieh CE, Lin CY, Lee LY, Yang LY, Wang CC, Wang HM, et al. Adding concurrent chemotherapy to postoperative radiotherapy improves locoregional control but not overall survival in patients with salivary gland adenoid cystic carcinoma-a propensity score matched study. Radiat Oncol. 2016;11:47. DOI: https://doi.org/10.1186/s13014-016-0617-7
Imamura Y, Kiyota N, Tahara M, Hanai N, Asakage T, Matsuura K, et al. Systemic therapy for salivary gland malignancy: current status and future perspectives. Jpn J Clin Oncol. 2022;52:293-302. DOI: https://doi.org/10.1093/jjco/hyac008
Sousa LG, Wang K, Torman D, Binks BJ, Rubin ML, Andersen CR, et al. Treatment patterns and outcomes of palliative systemic therapy in patients with salivary duct carcinoma and adenocarcinoma, not otherwise specified. Cancer. 2022;128:509-18. DOI: https://doi.org/10.1002/cncr.33968
Pinheiro J, Sa Fernandes M, Pereira AR, Lopes JM. Histological subtypes and clinical behavior evaluation of salivary gland tumors. Acta Med Port. 2018;31:641-7. DOI: https://doi.org/10.20344/amp.9023
Terhaard CH, Lubsen H, Van der Tweel I, Hilgers FJ, Eijkenboom WM, Marres HA, et al. Salivary gland carcinoma: independent prognostic factors for locoregional control, distant metastases, and overall survival: results of the Dutch head and neck oncology cooperative group. Head Neck. 2004;26:681-92. DOI: https://doi.org/10.1002/hed.10400
Speight PM, Barrett AW. Salivary gland tumours. Oral Dis. 2002;8:229-40. DOI: https://doi.org/10.1034/j.1601-0825.2002.02870.x
Uijen MJ, Lassche G, van Engen-van Grunsven AC, Tada Y, Verhaegh GW, Schalken JA, et al. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: a systematic review. Cancer Treat Rev. 2020;89:102069. DOI: https://doi.org/10.1016/j.ctrv.2020.102069
Lee RH, Wai KC, Chan JW, Ha PK, Kang H. Approaches to the management of metastatic adenoid cystic carcinoma. Cancers. 2022;14:5698. DOI: https://doi.org/10.3390/cancers14225698
Tosios KI, Papanikolaou V, Vlachodimitropoulos D, Goutas N. Primary large cell neuroendocrine carcinoma of the parotid gland. Report of a rare case. Head Neck Pathol. 2021;15:1377-84. DOI: https://doi.org/10.1007/s12105-021-01300-0
Liu M, Zhong M, Sun C. Primary neuroendocrine small cell carcinoma of the parotid gland: a case report and review of the literature. Oncol Lett. 2014;8:1275-8. DOI: https://doi.org/10.3892/ol.2014.2258
Na HG, Bae CH, Kim YD, Song SY, Choi YS. Primary small cell neuroendocrine carcinoma in the sublingual gland: a case report. Ear Nose Throat J. 2022;101:NP21-3. DOI: https://doi.org/10.1177/0145561320943064
Fushimi C, Tada Y, Takahashi H, Nagao T, Ojiri H, Masubuchi T, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. Ann Oncol. 2018;29:979-84. DOI: https://doi.org/10.1093/annonc/mdx771
Locati LD, Cavalieri S, Bergamini C, Resteghini C, Colombo E, Calareso G, et al. Abiraterone acetate in patients with castration-resistant, androgen receptor-expressing salivary gland cancer: a phase ii trial. J Clin Oncol. 2021;39:4061-4068. DOI: https://doi.org/10.1200/JCO.21.00468
Viscuse PV, Price KA, Garcia JJ, Schembri-Wismayer DJ, Chintakuntlawar AV. First line androgen deprivation therapy vs. chemotherapy for patients with androgen receptor positive recurrent or metastatic salivary gland carcinoma-a retrospective study. Front Oncol. 2019;9:701. DOI: https://doi.org/10.3389/fonc.2019.00701
Takahashi H, Tada Y, Saotome T, Akazawa K, Ojiri H, Fushimi C, et al. Phase II trial of trastuzumab and docetaxel in patients with human epidermal growth factor receptor 2-positive salivary duct carcinoma. J Clin Oncol. 2019;37:125-34. DOI: https://doi.org/10.1200/JCO.18.00545
Rached L, Saleh K, Casiraghi O, Even C. Salivary gland carcinoma: towards a more personalised approach. Cancer Treat Rev. 2024;124:102697. DOI: https://doi.org/10.1016/j.ctrv.2024.102697
Lassche G, van Boxtel W, Ligtenberg MJ, van Engen-van Grunsven AC, van Herpen CM. Advances and challenges in precision medicine in salivary gland cancer. Cancer Treat Rev. 2019;80:101906. DOI: https://doi.org/10.1016/j.ctrv.2019.101906
European Medicines Agency. Lynparza (olaparib). [cited 2024 Nov 18 2024]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza.
European Medicines Agency. Balversa (Erdafitinib). [cited 2024 Nov 18]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/balversa.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, et al. Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol.2023;24:925-35. DOI: https://doi.org/10.1016/S1470-2045(23)00275-9
de Bono J, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, et al. Olaparib for metastatic castration-resistant prostate cancer. N Engl J Med. 2020;382:2091-102. DOI: https://doi.org/10.1056/NEJMoa1911440
Joris S, Denys H, Collignon J, Rasschaert M, T’Kint de Roodenbeke D, Duhoux FP, et al. Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian precision tumor-agnostic phase II study. ESMO Open. 2023;8:102041. DOI: https://doi.org/10.1016/j.esmoop.2023.102041
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Acta Médica Portuguesa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
